Used as a potent inhibitor of Janus kinase 2 (JAK2), particularly effective in targeting the JAK2V617F mutation associated with myeloproliferative disorders. It shows strong activity in reducing abnormal cell proliferation in bone marrow, making it a candidate for treating conditions like polycythemia vera and myelofibrosis. Its hydroxylated imidamide structure enhances binding affinity to the ATP-binding site of JAK2, improving selectivity and potency. Also demonstrates anti-inflammatory effects due to modulation of cytokine signaling pathways. Currently investigated in preclinical and clinical studies for hematologic malignancies and autoimmune diseases.